Rationale for Intravenous Gamma-Globulin Therapy of Persistent Lymphotropic Viral Infections

  • P. J. Späth
Part of the Experimental Biology and Medicine book series (EBAM, volume 15)


Considerable clinical improvements reported in post-zoster neuralgia, X-linked lymphoproliferative syndrome, ARC or AIDS, autoimmune diseases as well as in chronic inflammatory disorders, following the administration of polyvalent intravenous immunoglobulin G (IVIG) (1), precipitated the idea to reconsider the rationale for IVIG therapy. Apparent therapeutic effects of IVIG can be subdivided into: A) substitution, B) modulation of cytokine release, and C) immunomodu-lation by idiotype-anti-idiotype (Id-aid) interactions. A) Substitution by IVIG can satisfy many of individual needs by substitution of the whole repertoire of the IgG class or of a single subclass in primary or secondary immunodeficiendes or by substitution of selective antibody deficiencies by clonal antibodies in otherwise immune competent patients. Substitution mediates antigen-directed actions as well as effector functions.


Chronic Inflammatory Disorder Peritoneal Exudate Cell Coagulation Factor Viii Immune Competent Patient Rabbit Peritoneal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    B. Perret, C. Baumgartner, Vox Sang. in pressGoogle Scholar
  2. 2.
    H. Besedowsky, A. del Rey, E. Sorkin, C.A. Dinarello, Science 233, 652 (1986)PubMedCrossRefGoogle Scholar
  3. 3.
    M. Iwata, R. Shimozato, H. Tokiwa, E. Tsubura, In: Clinical use of intravenous immunoglobulin, A. Morell, U.E. Nydegger, Eds. (Academic Press, London, 1986) pp 327–338Google Scholar
  4. 4.
    Y. Sultan, M.D. Kazatchkine, P. Maisonneuve, U.E. Nydegger, Lancet II 765 (1984)Google Scholar
  5. 5.
    A. Hässig, H. Cottier, Klin. Wschr. 64, 401 (1986)PubMedCrossRefGoogle Scholar

Copyright information

© The Humana Press Inc. 1987

Authors and Affiliations

  • P. J. Späth
    • 1
  1. 1.Bernese Immunoglobulin GroupCentral Laboratory of the Swiss Red CrossCH-3000 Bern-22Switzerland

Personalised recommendations